Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1a, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Healthy Adult Subjects

NCT05477160 is registered in ClinicalTrials.gov with Astria Therapeutics, Inc. as lead sponsor.

NCT NCT05477160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05477160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1a, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Healthy Adult Subjects
Lead sponsor
Astria Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 27, 2022
Completion date
November 17, 2023
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema